Living with HIV and Getting Vaccinated: A Narrative Review

Abstract

After 40 years of its appearance, human immunodeficiency virus (HIV) infection remains a leading public health challenge worldwide. Since the introduction of antiretroviral treatment (ART), HIV infection has become a chronic condition, and people living with HIV could have life expectancies close to those of the general population. People with HIV often have an increased risk of infection or experience more severe morbidity following exposure to vaccine-preventable diseases. Nowadays, several vaccines are available against bacteria and viruses. However, national and international vaccination guidelines for people with HIV are heterogeneous, and not every vaccine is included. For these reasons, we aimed to perform a narrative review about the vaccinations available for adults living with HIV, reporting the most updated studies performed for each vaccine among this population. We performed a comprehensive literature search through electronic databases (Pubmed—MEDLINE and Embase) and search engines (Google Scholar). We included English peer-reviewed publications (articles and reviews) on HIV and vaccination. Despite widespread use and guideline recommendations, few vaccine trials have been conducted in people with HIV. In addition, not all vaccines are recommended for people with HIV, especially for those with low CD4 cells count. Clinicians should carefully collect the history of vaccinations and patients’ acceptance and preferences and regularly check the presence of antibodies for vaccine-preventable pathogens.

What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study

“…Monoclonal antibodies (mAbs) were designed to target the SARS-CoV-2 spike protein and prevent the virus from entering host cells. Sotrovimab is one such mAb, which has shown promising results in clinical trials, with the potential to reduce the risk of hospitalization and death in COVID-19 patients [ 24 , 25 ].…”

Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study

“…Although the question of whether there is a benefit in combining dalbavancin with other antibiotics has not yet been elucidated, Cacopardo et al suggest that pairing dalbavancin with synergistic drugs suitable for each patient individually might be useful for specific infection categories, including bone and prosthetic joint infections (PJIs) or intravascular infections with no possibility of foreign material removal [20]. Dalbavancin use in off-label indications of infections by Gram-positive microorganisms has yielded promising results [5,[21][22][23][24]. The long list of treatment uses of dalbavancin includes consolidation therapy in acute infections [25], catheter-related staphylococcal bacteremia and Gram-positive bacteremia in general [21], infective endocarditis, osteomyelitis, spondylodiscitis, acute septic arthritis, diabetic foot infections, PJIs, suppressive treatment of chronic infections, and pneumonia [5].…”